Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma

Journal of Neuro-Oncology

Volumn 113, Issue 3, 2013, Pages 467-477

  Waters, J Dawn ^a   Rose, Brent ^b   Gonda, David D ^a   Scanderbeg, Daniel J ^c   Russell, Michelle ^c   Alksne, John F ^a   Murphy, Kevin ^c   Carter, Bob S ^a   Lawson, Joshua ^c   Chen, Clark C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Brachytherapy; Glioblastoma; Radiation; Safety; Temozolomide

Indexed keywords

(SODIUM 3 IODO 4 HYDROXYBENZENESULFONATE)IOTREX I 125; DEXAMETHASONE; ETIRACETAM; IRIDIUM 192; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE;

ADULT; AGED; AMNESIA; ARTICLE; BALLOON CATHETER; BRACHYTHERAPY; BRACHYTHERAPY DEVICE; BRAIN EDEMA; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; GLIOBLASTOMA; HEMIPARESIS; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARESTHESIA; POSTOPERATIVE COMPLICATION; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SEIZURE; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; ADJUVANT CHEMORADIOTHERAPY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; MORTALITY; POSTOPERATIVE PERIOD; PROGNOSIS; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRACHYTHERAPY; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CHEMORADIOTHERAPY, ADJUVANT; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS; SURVIVAL RATE;

EID: 84879410065     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1139-x     Document Type: Article

References (46)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. New Engl J Med 359(5):492-507
2. Walker MD et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49(3):333-343
3. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352(10):987-996
4. Pennington C et al (2006) A pilot study of brain tumour growth between radiotherapy planning and delivery. Clin Oncol 18(2):104-108
5. Pirzkall A et al (2009) Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 11(6):842-852
6. Dempsey JF et al (1998) Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain-tumor resection-cavity margins. Int J Radiat Oncol Biol Phys 42(2):421-429
7. Edmundson GK et al (2002) Dosimetric characteristics of the MammoSite RTS, a new breast brachytherapy applicator. Int J Radiat Oncol Biol Phys 52(4):1132-1139
8. Tatter SB et al (2003) An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg 99(2):297-303
9. Gutin PH et al (1984) Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. J Neurosurg 60(1):61-68
10. Gutin PH et al (1991) External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 21(3):601-606
11. Prados MD et al (1992) Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiat Oncol Biol Phys 24(4):593-597
12. Leibel SA et al (1989) Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 17(6):1129-1139
13. Scharfen CO et al (1992) High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 24(4):583-591
14. Laperriere NJ et al (1998) Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41(5):1005-1011
15. Gabayan AJ et al (2006) GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 58(4):701-709; discussion 701-709
16. Sanai N et al (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115(1):3-8
17. Lacroix M et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190-198
18. Kesari S et al (2011) DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. Future Oncol 7(11):1335-1346
19. Yoshimura J et al (2012) The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model. Childs Nerv Syst 28(5):707-713
20. Kil WJ et al (2008) In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 14(3):931-938
21. Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. British J Radiol 62(740):679-694
22. Wen PY et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963-1972
23. Radiation Therapy Oncology Group: Cooperative Group Common Toxicity Criteria. February 20, 2013. Available from: http://www.rtog.org/ ResearchAssociates/AdverseEventReporting/CooperativeGroupCommonToxicityCriteria. aspx
24. Lamborn KR et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10(2):162-170
25. Curran WJ Jr et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85(9):704-710
26. Mehta MP et al (1994) Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30(3):541-549
27. Shenouda G et al (1997) Radiosurgery and accelerated radiotherapy for patients with glioblastoma. Can J Neurol Sci 24(2):110-115
28. Ballman KV et al (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9(1):29-38
29. Combs SE et al (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23(34):8863-8869
30. Bristow RE et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248-1259
31. Chen AM et al (2007) Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69(3):825-830
32. Koot RW et al (2000) Brachytherapy: results of two different therapy strategies for patients with primary glioblastoma multiforme. Cancer 88(12):2796-2802
33. Welsh J et al (2007) GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys 68(1):159-165
34. Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 352(10):997-1003
35. Noushmehr H et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510-522
36. Souhami L et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60(3):853-860
37. Fulton DS et al (1992) Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study. J Neurooncol 14(1):63-72
38. Lustig RA et al (2007) Imaging response in malignant glioma, RTOG 90-06. Am J Clin Oncol 30(1):32-37
39. Coughlin C et al (2000) Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (>20 or ≤20 cm (2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys 48(5):1351-1358
40. Tsien C et al (2009) Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys 73(3):699-708
41. Patel S et al (2000) Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 46(5):1123-1128; discussion 1128-1130
42. Larson DA et al (2004) Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 6(2):119-126
43. Selker RG et al (2002) The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, intersitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51(2):345-355; discussion 355-357
44. Mclendon RE et al (2007) Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol 34(4):405-413
45. Sneed PK et al (1996) Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 35(1):37-44
46. Wen PY et al (1994) Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer 73(12):3029-3036